Using data from the National HIV Surveillance System, the National Center for Health Statistics, and the US Census, a team from the CDC investigated lifetime HIV risk in the United States.
Persistent disparities in the lifetime risk of an HIV diagnosis between females and males, as well as among races and ethnicities, highlight the ongoing need to step up education and prevention efforts in the United States, CDC researchers noted in a presentation at this year’s Conference on Retroviruses and Opportunistic Infections.
These investigators utilized data on HIV diagnosis, mortality, and census population from the National HIV Surveillance System, the National Center for Health Statistics, and the US Census, respectively. Probability of an HIV diagnosis at any age was calculated via HIV diagnoses and non-HIV deaths from 2017 to 2019 and compared with similar data from 2010 through 2014.
“Estimating the lifetime risk may be a useful tool for clinicians, partners, and policy makers when describing the burden of HIV since it can be more readily understood by the public,” the authors wrote. “Estimates of lifetime risk are used to compare the burden of disease across populations.”
Overall, their numbers show a 1 in 120 lifetime risk of an HIV diagnosis for 2017 to 2019 vs 1 in 106 for 2010 to 2014, which is an 11% improvement.
When comparing this outcome between females and males, the risk was lower for females (1 in 309) and greater for males (1 in 76), so that the latter had a 4 times greater risk of an HIV diagnosis.
Also, when stratifying risk by race, females had a universal lower lifetime risk of HIV vs males:
Further, when comparing 2010 to 2014 and 2017 to 2019, lifetime risk was shown to be down for most groups. The exceptions were males of American Indian/Alaska Native, Hispanic/Latino, and Native Hawaiian/other Pacific Islander descent and White females.
Breaking the findings down by state and jurisdiction, the highest overall risks were seen in Washington, DC (1 in 39); followed by Georgia (1 in 59); Florida (1 in 63); Louisiana (1 in 69); Nevada (1 in 84); and Maryland (1 in 85). The lowest risks were in Vermont (1 in 515), New Hampshire (1 in 533), Montana (1 in 536), Maine (1 in 584), Idaho (1 in 624), and Wyoming (1 in 655).
When summing the investigators’ findings, lead author Sonia Singh, PhD, from the CDC’s Division of HIV Prevention, noted that their findings assume “the rate of infection will continue [and] that prevention efforts work,” as evidenced by the decline seen between the 2 periods.
However, there is still need for continued progress in HIV prevention and treatment because of the ongoing risk disparities.
Reference
Singh S, Hu X, Hess K. Estimating the lifetime risk of a diagnosis of HIV infection in the United States. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; Virtual. Abstract 43. https://www.croiconference.org/abstract/estimating-the-lifetime-risk-of-a-diagnosis-of-hiv-infection-in-the-united-states/
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More